Detalhe da pesquisa
1.
A Phase 1 study for safety and pharmacokinetics of BIO101 (20-hydroxyecdysone) in healthy young and older adults.
J Cachexia Sarcopenia Muscle
; 14(3): 1259-1273, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37057316
2.
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.
Cancer Chemother Pharmacol
; 74(2): 257-65, 2014 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-24880570